Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
ACS Appl Mater Interfaces ; 16(10): 13103-13113, 2024 Mar 13.
Artículo en Inglés | MEDLINE | ID: mdl-38422366

RESUMEN

Ionogels have great potential for the development of tissue-like, soft, and stretchable ionotronics. However, conventional isotropic ionogels suffer from poor mechanical properties, low efficient force transmission, and tardy mechanoelectric response, hindering their practical utility. Here, we propose a simple one-step method to fabricate bioinspired anisotropic nanocomposite ionogels based on a combination of strain-induced phase separation and mechanomodulation of ionic conduction in the presence of attapulgite nanorods. These ionogels show high stretchability (747.1% strain), tensile strength (6.42 MPa), Young's modulus (83.49 MPa), and toughness (18.08 MJ/m3). Importantly, the liquid crystalline domain alignment-induced microphase separation and ionic conductivity enhancement during stretching endow these ionogels with an unusual mechanoelectric response and dual-programmable shape-memory properties. Moreover, the anisotropic structure, good elasticity, and unique resistance-strain responsiveness give the ionogel-based strain sensors high sensitivity, rapid response time, excellent fatigue resistance, and unique waveform-discernible strain sensing, which can be applied to real-time monitoring of human motions. The findings offer a promising way to develop bioinspired anisotropic ionogels to modulate the microstructure and properties for practical applications in advanced ionotronics.

2.
J Nanobiotechnology ; 22(1): 20, 2024 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-38183048

RESUMEN

BACKGROUND: Radiotherapy is one of the mainstays of cancer therapy and has been used for treating 65-75% of patients with solid tumors. However, radiotherapy of tumors has two limitations: high-dose X-rays damage adjacent normal tissue and tumor metastases cannot be prevented. RESULTS: Therefore, to overcome the two limitations of radiotherapy, a multifunctional core-shell R837/BMS@Au8 nanoparticles as a novel radiosensitizer were fabricated by assembling Au8NCs on the surface of a bifunctional nanoimmunomodulator R837/BMS nanocore using nanoprecipitation followed by electrostatic assembly. Formed R837/BMS@Au8 NP composed of R837, BMS-1, and Au8 clusters. Au8NC can enhance X-ray absorption at the tumor site to reduce X-ray dose and releases a large number of tumor-associated antigens under X-ray irradiation. With the help of immune adjuvant R837, dendritic cells can effectively process and present tumor-associated antigens to activate effector T cells, meanwhile, a small-molecule PD-L1 inhibitor BMS-1 can block PD-1/PD-L1 pathway to reactivate cytotoxic T lymphocyte, resulting in a strong systemic antitumor immune response that is beneficial for limiting tumor metastasis. According to in vivo and in vitro experiments, radioimmunotherapy based on R837/BMS@Au8 nanoparticles can increase calreticulin expression on of cancer cells, reactive oxygen species generation, and DNA breakage and decrease colony formation. The results revealed that distant tumors were 78.2% inhibited depending on radioimmunotherapy of primary tumors. Therefore, the use of a novel radiosensitizer R837/BMS@Au8 NPs realizes low-dose radiotherapy combined with immunotherapy against advanced cancer. CONCLUSION: In conclusion, the multifunctional core-shell R837/BMS@Au8 nanoparticles as a novel radiosensitizer effectively limiting tumor metastasis and decrease X-ray dose to 1 Gy, providing an efective strategy for the construction of nanosystems with radiosensitizing function.


Asunto(s)
Neoplasias , Fármacos Sensibilizantes a Radiaciones , Humanos , Adyuvantes Inmunológicos , Imiquimod , Neoplasias/radioterapia , Fármacos Sensibilizantes a Radiaciones/farmacología , Radioinmunoterapia , Oro/química
3.
Acta Biomater ; 176: 234-249, 2024 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-38218359

RESUMEN

Thrombosis and intimal hyperplasia (IH) are two major problems faced by the small-diameter vascular grafts. Mimicking the native endothelium and physiological elasticity of blood vessels is considered an ideal strategy. Polyurethane (PU) is suitable for vascular grafts in mechanics because of its molecular designability and elasticity; however, it generally lacks the endothelium-like biofunctions and hydrophilicity. To solve this contradiction, a hydrophilic PU elastomer is developed by crosslinking the hydrophobic hard-segment chains containing diselenide with diaminopyrimidine-capped polyethylene glycol (PEG). In this network, the hydrophobic aggregation occurs underwater due to the uninterrupted hard-segment chains, leading to a significant self-enhancement in mechanics, which can be tailored to the elasticity similar to natural vessels by adjusting the crosslinking density. A series of in vitro studies confirm that the hydrophilicity of PEG and biological activities of aminopyrimidine and diselenide give the PU multi-biological functions similar to the native endothelium, including stable catalytic release of nitric oxide (NO) in the physiological level; anti-adhesion and anti-activation of platelets; inhibition of migration, adhesion, and proliferation of smooth muscle cells (SMCs); and antibacterial effect. In vivo studies further prove the good histocompatibility with both significant reduction in immune response and calcium deposition. STATEMENT OF SIGNIFICANCE: Constructing small-diameter vascular grafts similar to the natural vessels is considered an ideal method to solve the restenosis caused by thrombosis and intimal hyperplasia (IH). Because of the long-term stability, bulk modification is more suitable for implanted materials, however, how to achieve the biofunctions, hydrophilicity, and elasticity simultaneously is still a big challenge. In this work, a kind of polyurethane-based elastomer has been designed and prepared by crosslinking the functional long hard-segment chains with PEG soft segments. The underwater elasticity based on hydration-induced stiffening and the multi-biological functions similar to the native endothelium are compatible with natural vessels. Both in vitro and in vivo experiments demonstrate the potential of this PU as small-diameter vascular grafts.


Asunto(s)
Poliuretanos , Trombosis , Humanos , Poliuretanos/farmacología , Poliuretanos/química , Elastómeros/farmacología , Hiperplasia , Prótesis Vascular , Interacciones Hidrofóbicas e Hidrofílicas
4.
J Environ Manage ; 336: 117660, 2023 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-36893536

RESUMEN

In this study, hexavalent chromium Removal from aqueous environments was investigated by using polyaniline composites with some natural waste materials. Batch experiments were used, and some parameters such as contact time, pH and adsorption isotherms were determined for the best composite with the highest removal efficiency. Scanning Electron Microscope (SEM), Fourier Transform Infrared (FTIR) spectroscopy, and X-ray Diffraction (XRD) were used to characterize the composites. According to the results, the polyaniline/walnut shell charcoal/PEG composite outperformed other composites and showed the highest chromium removal efficiency of 79.22%. Polyaniline/walnut shell charcoal/PEG has a larger specific surface area of 9.291 (m2/gr) which leads to an increase in its removal efficiency. For this composite, the highest removal efficiency was obtained at the pH = 2 and 30 min contact time. The maximum calculated adsorption capacity was 500 mg/g.


Asunto(s)
Contaminantes Químicos del Agua , Purificación del Agua , Carbón Orgánico/química , Contaminantes Químicos del Agua/química , Compuestos de Anilina , Cromo/química , Adsorción , Agua , Espectroscopía Infrarroja por Transformada de Fourier , Cinética , Concentración de Iones de Hidrógeno , Purificación del Agua/métodos
5.
Biomed Mater ; 18(3)2023 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-36731137

RESUMEN

Mimicking the multilayered structure of blood vessels and constructing a porous inner surface are two effective approaches to achieve mechanical matching and rapid endothelialization to reduce occlusion in small-diameter vascular grafts. However, the fabrication processes are complex and time consuming, thus complicating the fabrication of personalized vascular grafts. A simple and versatile strategy is proposed to prepare the skeleton of vascular grafts by rolling self-adhesive polymer films. These polymer films are directly fabricated by dropping a polymer solution on a water surface. For the tubes, the length and wall thickness are controlled by the rolling number and position of each film, whereas the structure and properties are tailored by regulating the solution composition. Double-layer vascular grafts (DLVGs) with microporous inner layers and impermeable outer layers are constructed; a microporous layer is formed by introducing a hydrophilic polymer into a polyurethane (PU) solution. DLVGs exhibit a J-shaped stress-strain deformation profile and compliance comparable to that of coronary arteries, sufficient suture retention strength and burst pressure, suitable hemocompatibility, significant adhesion, and proliferation of human umbilical vein endothelial cells. Freshly prepared PU tubes exhibit good cytocompatibility. Thus, this strategy demonstrates potential for rapid construction of small-diameter vascular grafts for individual customization.


Asunto(s)
Células Endoteliales , Agua , Humanos , Prótesis Vascular , Esqueleto , Polímeros , Poliuretanos/química
6.
Health Phys ; 2022 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-36223337

RESUMEN

ABSTRACT: Relevant studies have confirmed that the stimulation of spleen function caused by low-dose splenic irradiation can have positive effects on tumors and other diseases. This study aimed to determine radiation-induced changes in spleen index, lymphocyte subsets, spleen cell apoptosis, and pathological features of the spleen in mice. The mouse model was established by irradiating the spleen at different doses. The mice were divided into the following groups: blank control, low-dose, low-dose fractionated irradiation, and challenge dose irradiation. The mice were sacrificed under humanitarian conditions, and spleen tissue and peripheral blood were collected. The spleen index was calculated, and flow cytometry was used to analyze spleen T lymphocyte subsets and spleen apoptosis. The pathological changes in the spleen were determined by hematoxylin and eosin (H&E) staining. The spleen index of mice in the low-dose fractionated irradiation group was significantly increased compared with that in the blank control group. The spleen indexes of the low-dose irradiation and low-dose fractionated irradiation groups were much higher than that of the challenge dose irradiation group. Compared with the blank control group, the percentage of CD3+ and CD4+ T lymphocytes in the peripheral blood and spleen tissues in the low-dose irradiation and low-dose fractionated irradiation groups was significantly increased, whereas that from the challenge dose irradiation group was obviously decreased. CD8+ T lymphocytes in the peripheral blood and spleen tissues in the low-dose irradiation, low-dose fractionated irradiation, and challenge dose irradiation groups were significantly lower than those in the blank control group. The apoptosis rate of the spleen in the challenge dose irradiation group was significantly higher than that in the blank control, low-dose irradiation, and low-dose fractionated irradiation groups. H&E staining analysis of the spleen showed pathological changes in the different irradiation groups compared with the blank control group. Low-dose irradiation and low-dose fractionated irradiation can change the T lymphocyte subsets in the peripheral blood and spleen of mice, which can promote immune excitation and improve immune effects.

7.
Water Res ; 225: 119134, 2022 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-36182672

RESUMEN

The bismuth oxide (Bi2O3) based chloride (Cl-) removal method is one of the chemical precipitation methods possessing good selectivity and high removal efficiency of Cl- ions, but Bi2O3 often appears in the powder form, which is difficult to be recovered for regeneration. In this work, the combination of 3D printing technology and the Bi2O3 method was explored to construct the resin model including the Bi-precursors. In the optimum carbonization process at 400 °C for 30 min, the Bi3+ ions of the Bi-precursor were reduced into the metallic Bi0 nanoparticles, whose surfaces were covered by the thin Bi2O3 layers to form the heterostructured Bi0/Bi2O3 core/shell nanoparticles with an average size of 43 nm. These Bi0/Bi2O3 nanoparticles were tightly adhered to the internal and external surfaces of the hierarchical porous carbon model (Bi-PCM), which greatly facilitated their regeneration and ensured the stable Cl- removal performance. After five cycles of Cl- removal, the chloride removal efficiency over the multiple Bi-PCMs in the dark and pH 1 conditions maintained at about 26%, which then largely increased to 63.6% with UV light irradiation. The light-enhanced mechanism was related to the improved release rate of Bi3+ ions caused by photocorrosion and the Cl• radicals produced from the holes and the •OH and O2•- radicals, which quickly reacted with Bi2O3 to form BiOCl. The construction of Bi-PCMs by using 3D printing technology provides a very promising strategy for the removal of Cl- ions from wastewater.


Asunto(s)
Bismuto , Aguas Residuales , Cloruros , Carbono , Porosidad , Polvos , Halógenos , Impresión Tridimensional , Tecnología
8.
Front Oncol ; 12: 908759, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35912232

RESUMEN

Background: The genomic features of cancer cells may confer the metastatic ability of lung adenocarcinoma (LUAD) to metastasize to specific organs. We aimed to identify the differences in genomic alterations between patients with primary LUAD with and without metastases and to elucidate the metastatic biology that may help developing biomarker-directed therapies for advanced or metastatic disease. Methods: A retrospective cohort of 497 patients with LUAD including 388 primary tumors (PR), 53 bone metastases (MT-bone), 30 liver metastases (MT-liver), and 26 brain metastases (MT-brain) was tested for genomic alterations by a next-generation sequencing assay. Results: The EGFR, TP53, TERT, LRP1B, CDKN2A, ERBB2, ALK, and KMT2C genes had a high frequency of mutations, and the mutations were shared by PR and metastases groups. TP53 and EGFR were the most common mutated genes. In comparison with PR, KRAS, STK11, ATM, NPM1, and ROS1 were significantly mutated in MT-brain, and TP53, MYC, RSPO2, CDKN2a, and CDKN2B were significantly mutated in MT-liver. The frequencies of TP53, CDKN2A, MTAP, PRKCI, and APC mutations were higher in MT-bone than that in PR. The ERBB, phosphoinositide-3-kinase/protein kinase B (PI3K-AKT), cell cycle, Fibroblast growth factor (FGF), and homologous recombination deficiency signaling pathways were affected in both PR and metastases, and there is higher frequency of mutations in metastases. Moreover, the co-mutations in patients with PR and metastasis were respectively analyzed. In addition, the programmed death ligand 1 (PD-L1) level was obviously related to tumor stage and tumor metastases, and the tumor mutational burden was correlated to clinicopathological features including age, gender, pathological stages, and tumor metastases. FGFR1, KAT6A, MYC, RAD21, TP53, and DAXX were also dramatically correlated to the tumor mutational burden. Conclusion: Metastases are the most devastating stage of tumors and the main cause of cancer-related deaths. Our results provided a clinically relevant view of the tumor-intrinsic mutational landscape of patients with metastatic LUAD.

9.
Front Chem ; 10: 807088, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35330702

RESUMEN

Dual-state emission (DSE) luminogens, a type of luminescent material which can effectively emit light in both dilute solution and solid states, have attracted tremendous attention, due to their widespread applications in chemical sensing, biological imaging, organic electronic devices, and so on. They overcome the shortcomings of aggregation-induced emission (AIE)-type compounds that do not emit light in dilute solutions and aggregation-caused quenching (ACQ)-type compounds that do not emit light in a concentrated or aggregated state. This work reports a novel ionic DSE material based on rigid rod-shaped organic conjugated structure using 4,4'-bis(2-sulfonatostyryl) biphenyl disodium salt (BSBDS); the ion repulsion effect can reduce the strong π-π interaction in aggregation and achieve high-efficiency luminescence in solution and solid states. In addition to excellent DSE characteristics, BSBDS also exhibits a mechanochromic nature and sensitive detection performance for aluminum ion (Al3+).

10.
Bioengineered ; 13(3): 6711-6718, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-35246018

RESUMEN

Circular RNA (circRNA) hsa_circ_0077837 inhibits colorectal cancer. Our research studied the participation of hsa_circ_0077837 in non-small cell lung cancer (NSCLC). Hsa_circ_0077837 and phosphatase and tensin homolog (PTEN) expression in cancer and paired non-cancer tissues from a total of 64 NSCLC patients were studied with RT-qPCR. To evaluate the prognostic value of hsa_circ_0077837 for NSCLC, these 64 patients were monitored for 5 years. Expression of PTEN in NSCLC cells with hsa_circ_0077837 overexpression was determined by RT-qPCR and Western blot. The methylation of PTEN gene in cells transfected with hsa_circ_0077837 expression vector was analyzed by methylation specific PCR (MSP). The roles of hsa_circ_0077837 and PTEN in NSCLC cell proliferation were evaluated using cell apoptosis assay. Our data showed that hsa_circ_0077837 was upregulated in NSCLC and predicted poor survival. Besides, hsa_circ_0077837 expression level was higher in 36 advanced cases (stage III and IV) than in 28 early-stage cases (stage I and II). Hsa_circ_0077837 was inversely correlated with PTEN across cancer tissues. In NSCLC cells, hsa_circ_0077837 overexpression decreased PTEN expression, increased PTEN gene methylation, and reduced HCC827 cell apoptosis via PTEN. Overall, hsa_circ_0077837 is upregulated in NSCLC and downregulates PTEN by increasing its gene methylation to suppress cell apoptosis.List of abbreviations:Non-small cell lung cancer (NSCLC); circRNAs (circular RNAs); methylation-specific PCR (MSP).


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , MicroARNs , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Línea Celular Tumoral , Proliferación Celular/genética , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Metilación , MicroARNs/metabolismo , ARN Circular/genética , Tensinas/metabolismo
11.
J Mater Chem B ; 9(42): 8809-8822, 2021 11 03.
Artículo en Inglés | MEDLINE | ID: mdl-34633023

RESUMEN

Designing a multi-target nanomedicine without a carrier is pivotal for successful cancer nanotherapy. This study details a novel four-in-one RRX/BMS/CA4/PTX nanomedicine by simple nanoprecipitation. In this multi-target pure nanomedicine, paclitaxel (PTX) causes the immunogenic cell death of 4T1 tumour cells and the differentiation of marrow-derived suppressor cells (MDSCs) into dendritic cells (DCs) at low dose; repertaxin (RRX) selectively depletes cancer stem cells (CSCs) that are not killed by paclitaxel to inhibit lung metastasis from the breast; BMS-1 blocks the PD-1/PD-L1 pathway for proliferating effector T cells; and combretastatin A4 (CA4) targets tumour microvessels to cut off the blood supply in the tumour microenvironment. The synergy of multi-target therapies results in excellent antitumour effects. The tumour inhibition rate of 4T1 tumours is 92.5%, and the lung metastasis suppression rate exceeds 90%; no relapse is observed at 46 days after the treatment endpoint, and the survival of 50% of mice is prolonged by 95 days. Due to the low dose of PTX administration, the systemic toxicity of the RRX/BMS/CA4/PTX nanomedicine is not found. Our results suggest a strategy for designing multi-target pure nanomedicines with simple construction and efficacious therapeutic responses that present potential for clinical transformation.


Asunto(s)
Antineoplásicos , Neoplasias de la Mama , Nanomedicina , Paclitaxel , Estilbenos , Sulfonamidas , Animales , Femenino , Ratones , Antineoplásicos/química , Antineoplásicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Ratones Endogámicos BALB C , Estructura Molecular , Paclitaxel/química , Paclitaxel/farmacología , Estilbenos/química , Estilbenos/farmacología , Sulfonamidas/química , Sulfonamidas/farmacología
12.
J Mater Chem B ; 9(36): 7544-7556, 2021 09 22.
Artículo en Inglés | MEDLINE | ID: mdl-34551052

RESUMEN

Immunosuppressed tumor microenvironment (TME) is a major cause of the low response rate in solid tumor patients during PD-1/PD-L1 checkpoint blockade therapy. In this study, a series of small molecule nanomedicines with a 100% drug loading rate were prepared via the nanoprecipitation method. They were used in synergistic chemo-immunotherapy for 4T1 tumors. Among four PD-L1 small-molecule nanoinhibitors, BMS-1 NP with the best anti-tumor performance was selected to replace the therapeutic PD-L1 antibody. The core-shell small-molecule nanomedicine DTX@VTX NP (DTX: Docetaxel and VTX: VTX-2337 or Motolimod) was used to reverse immunosuppressed TME through the depletion of myeloid-derived suppressor cells (MDSCs) and the polarization of macrophages from an M2-like phenotype to M1-like phenotype. Thus, the frequency of cytotoxic CD8+ T cells was significantly increased, resulting in an effective attack on cancer cells. Combining BMS-1 NPs with DTX@VTX NPs, synergistic chemo-immunotherapy of 4T1 tumors was performed, and the results indicate that the inhibition rates of primary and rechallenge tumors achieved 90.5% and 94.3%, respectively. These results indicate that DTX@VTX NPs can synergize PD-L1 nanoinhibitor BMS-1 NPs to reshape the immunosuppressive tumor microenvironment for enhancing the anti-tumor effect of chemo-immunotherapy for breast.


Asunto(s)
Antineoplásicos/química , Benzazepinas/química , Docetaxel/química , Factores Inmunológicos/química , Nanopartículas/química , Bibliotecas de Moléculas Pequeñas/química , Animales , Antineoplásicos/uso terapéutico , Antígeno B7-H1/antagonistas & inhibidores , Antígeno B7-H1/metabolismo , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Línea Celular Tumoral , Docetaxel/uso terapéutico , Sinergismo Farmacológico , Femenino , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico , Inmunoterapia , Ratones , Ratones Endogámicos BALB C , Nanopartículas/metabolismo , Nanopartículas/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Neoplasias/terapia , Trasplante Homólogo , Microambiente Tumoral/efectos de los fármacos
13.
Med Princ Pract ; 30(4): 376-384, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33823519

RESUMEN

OBJECTIVE: The objective of the present study was to determine a target gene and explore the molecular mechanisms involved in the pathogenesis of HER-2-positive breast cancer. METHODS: Three RNA expression profiles obtained from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) were used to identify differentially expressed genes (DEGs) using the R software. A protein-protein interaction network was then constructed, and hub genes were determined. Subsequently, the relationship between clinical parameters and hub genes was examined to screen for target genes. Next, DNA methylation and genomic alterations of the target gene were evaluated. To further explore potential molecular mechanisms, a functional enrichment analysis of genes coexpressed with the target gene was performed. RESULTS: The differential expression analysis revealed 217 DEGs in HER-2-positive breast cancer samples compared to normal breast tissues. RRM2 was the only hub gene closely associated with lymphatic metastasis and the patients' prognosis. Additionally, RRM2 was found to be consistently amplified and negatively associated with the level of methylation. Functional enrichment analysis showed that the coexpressed genes were mainly involved in cell cycle regulation. CONCLUSIONS: RRM2 was identified as a target gene associated with the initiation, progression, and prognosis of HER-2-positive breast cancer, which may be considered as a new biomarker and therapeutic target.


Asunto(s)
Neoplasias de la Mama , Biología Computacional , Perfilación de la Expresión Génica/métodos , Metástasis Linfática/genética , Ribonucleósido Difosfato Reductasa/genética , Adulto , Anciano , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Metilación de ADN , Detección Precoz del Cáncer , Femenino , Genómica , Humanos , Persona de Mediana Edad , Pronóstico , Receptor ErbB-2 , Análisis de Supervivencia
14.
J Mater Chem B ; 9(10): 2548, 2021 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-33660734

RESUMEN

Correction for 'On-demand removable hydrogels based on photolabile cross-linkings as wound dressing materials' by Haiyang Wu et al., J. Mater. Chem. B, 2019, 7, 5669-5676, DOI: 10.1039/C9TB01544B.

15.
Ann Palliat Med ; 9(4): 2347-2352, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32762231

RESUMEN

Small cell lung cancer (SCLC) is an invasive lung cancer subtype. Despite its sensitivity to first-line chemotherapy, SCLC has a high recurrence rate and poor response to second-line therapy. Recently, immunotherapy has shown promise as a novel therapy for the treatment of SCLC. One immune-checkpoint inhibitor, pembrolizumab, has demonstrated antitumor activity in patients with SCLC. In June 2019, based on data from the KEYNOTE-28 and KEYNOTE-158 trial, the US Food and Drug Administration (FDA) approved pembrolizumab for treatment of metastatic SCLC patients who had made progress on a platinum-based chemotherapy and at least one other line of therapy. Herein, we reported an 86-year-old female patient with extensive-stage disease (ED-SCLC) who was treated with pembrolizumab after relapse following first-line therapy and achieved a complete response (CR) in only one month after initiation of treatment. This case highlights that patients with ED-SCLC may benefit from immunotherapy and identifies a clinically meaningful therapeutic option.


Asunto(s)
Neoplasias Pulmonares , Carcinoma Pulmonar de Células Pequeñas , Anciano de 80 o más Años , Anticuerpos Monoclonales Humanizados/uso terapéutico , Femenino , Humanos , Inmunoterapia , Neoplasias Pulmonares/tratamiento farmacológico , Carcinoma Pulmonar de Células Pequeñas/tratamiento farmacológico
16.
ACS Biomater Sci Eng ; 6(6): 3529-3538, 2020 06 08.
Artículo en Inglés | MEDLINE | ID: mdl-33463187

RESUMEN

Injectable hydrogels have become increasingly important in the fields of tissue engineering and drug delivery. However, their biological applications are greatly limited by the weak mechanics and poor stability under a physiological environment. Herein, we developed a stable, strong, and injectable hydrogel by linking strong micelle cross-linking with tetra-armed PEG. This dual cross-linking strategy has not only made hydrogels nonswelling but also maintained the relative integrity of the gel network during the degradation process, both of which work together to ensure the mechanical strength and stability of our hydrogel under a physiological environment. A compressive stress of 40 MPa was achieved at 95% strain, and the mechanical properties could remain stable even after immersion into a physiological environment for two months. Besides, it also showed outstanding antifatigue properties, good tissue adhesion, and good cytocompatibility. On the basis of these characteristics, these dual cross-linking injectable hydrogels would find appealing application in biomedicine especially for the repair of load-bearing soft tissues.


Asunto(s)
Hidrogeles , Ingeniería de Tejidos , Sistemas de Liberación de Medicamentos , Micelas
17.
Cancer Biol Ther ; 21(1): 26-33, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31594446

RESUMEN

There is still limited comprehensive genotyping data about young patients with lung adenocarcinoma. Herein, next generation sequencing (NGS) data of lung adenocarcinoma patients was retrospectively analyzed to evaluate the relationship between young age at diagnosis and the comprehensive molecular characteristics. The cBioPortal for Cancer Genomics database was queried for cancer genomic studies of lung adenocarcinoma and a cohort of 773 patients with complete cancer genomics data was selected from 2 of 11 studies. The relationship between age at diagnosis and frequency of targetable genotypes was analyzed and verified in another cohort composed of 177 Chinese lung adenocarcinoma patients undergoing NGS assay. Of the 773 eligible lung adenocarcinoma patients, younger age was associated with an increased likelihood of a targetable genotype (P < .001). Specifically, a higher prevalence of EGFR mutations (P = .005), ALK arrangements, ROS1 arrangements (P = .035) and RET arrangements (P < .001) were identified in younger patients. The frequency of KRAS mutations (P < .001) was significantly associated with older age at diagnosis and a similar trend existed for MET (P = .057) but not BRAF-V600E (P = .686) and ERBB2 (P = .083). Additionally, an age at diagnosis of 45 years was found to be a feasible cutoff point to differentiate the younger from the older patients by comprehensive molecular characteristics. These results indicated that younger patients with lung adenocarcinoma were associated with an increased likelihood of harboring a targetable genotype. Distinctive molecular characteristics were identified in patients younger than 45 years with lung adenocarcinoma, which highlights the importance of the NGS assay and personalized therapy in this subpopulation.


Asunto(s)
Adenocarcinoma del Pulmón/genética , Biomarcadores de Tumor/genética , Regulación Neoplásica de la Expresión Génica , Genómica/métodos , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Neoplasias Pulmonares/genética , Mutación , Adenocarcinoma del Pulmón/patología , Adulto , Anciano , Anciano de 80 o más Años , Bases de Datos Factuales , Femenino , Estudios de Seguimiento , Genotipo , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos
18.
Small ; 15(49): e1903881, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31702880

RESUMEN

Targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immunologic checkpoint blockade with monoclonal antibodies has achieved recent clinical success in antitumor therapy. However, therapeutic antibodies exhibit several issues such as limited tumor penetration, immunogenicity, and costly production. Here, Bristol-Myers Squibb nanoparticles (NPs) are prepared using a reprecipitation method. The NPs have advantages including passive targeting, hydrophilic and nontoxic features, and a 100% drug loading rate. BMS-202 is a small-molecule inhibitor of the PD-1/PD-L1 interaction that is developed by BMS. Transfer of BMS-202 NPs to 4T1 tumor-bearing mice results in markedly slower tumor growth to the same degree as treatment with anti-PD-L1 monoclonal antibody (α-PD-L1). Consistently, the combination of Ce6 NPs with BMS-202 NPs or α-PD-L1 in parallel shows more efficacious antitumor and antimetastatic effects, accompanied by enhanced dendritic cell maturation and infiltration of antigen-specific T cells into the tumors. Thus, inhibition rates of primary and distant tumors reach >90%. In addition, BMS-202 NPs are able to attack spreading metastatic lung tumors and offer immune-memory protection to prevent tumor relapse. These results indicate that BMS-202 NPs possess effects similar to α-PD-L1 in the therapies of 4T1 tumors. Therefore, this work reveals the possibility of replacing the antibody used in immunotherapy for tumors with BMS-202 NPs.


Asunto(s)
Antígeno B7-H1/metabolismo , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/terapia , Fotoquimioterapia/métodos , Receptor de Muerte Celular Programada 1/metabolismo , Animales , Femenino , Humanos , Inmunoterapia , Ratones , Ratones Endogámicos BALB C , Nanopartículas/química , Recurrencia Local de Neoplasia/metabolismo , Recurrencia Local de Neoplasia/terapia
19.
ACS Appl Mater Interfaces ; 11(41): 37479-37490, 2019 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-31532613

RESUMEN

The tissue penetration depth of light and the singlet oxygen (1O2) generation efficiency of photosensitizers (PSs) are the two main factors that determine the effectiveness of photodynamic therapy for tumors. Herein, we report a novel strategy to prepare a multifunctional upconversion photosensitizer (UCPS) based on the host/guest nanoarchitecture. By a simple reprecipitation method, host/guest tetracene/pentacene nanorods (Tc/Pc NRs) were synthesized for enhancing triplet-triplet annihilation-upconversion (TTA-UC) or two-photon excited emission and 1O2 generation efficiency upon 650 or 808 nm excitation. Tc/Pc NRs had higher 1O2 quantum yield (74%) than Tc NRs (28%) upon 650 nm laser irradiation. The proposed mechanism is that doping Pc molecules into Tc NRs induces intermediate states between S0 and S1, shortening the energy gap for 1O2 generation and resulting in TTA-UC emission. Equally important, with 808 nm fs laser excitation, Tc/Pc NRs showed an enhanced 1O2 generation efficiency and two-photon absorption cross section (σ) compared with Tc NRs. In addition, when the tumors in mice were exposed to Tc/Pc NRs with 650 or 808 nm wavelength irradiation, the tumor inhibition rates achieved 99 and 95%, respectively. This work opens new perspectives for exploring novel nano-UCPSs for biomedical applications.


Asunto(s)
Nanotubos/química , Naftacenos , Neoplasias Experimentales/tratamiento farmacológico , Fotoquimioterapia , Animales , Células HeLa , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Naftacenos/química , Naftacenos/farmacología , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología
20.
Adv Healthc Mater ; 8(20): e1900582, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31529779

RESUMEN

Thrombus and restenosis are two main factors that cause the failure of vascular implants. Constructing a functional and confluent layer of endothelial cells (ECs) is considered an ideal method to prevent these problems. However, oxidative stress induced by the disease and implantation can damage ECs and hinder the endothelialization of implants. Thus, developing biomaterials that can protect ECs adhesion and proliferation from oxidative stress is urgently needed for the rapid endothelialization of vascular implants. In this work, a novel polyurethane (PU-TBN) is synthesized by employing tetramethylpyrazine-nitrone (TBN) as end-group to endow polymers with dual functions of antioxidant activity and promoting endothelialization. Common PU without TBN is also prepared to be control. Compared to PU, PU-TBN significantly promotes human umbilical vein endothelial cells (HUVECs) adhesion and proliferation, where cells spread well and a confluent endothelial layer is formed. PU-TBN also shows obvious free radical scavenging activity, and thus effectively attenuates oxidative stress to protect HUVECs from oxidative apoptosis. Moreover, PU-TBN exhibits enhanced antiplatelets effect, excellent biocompatibility, and similar mechanical properties to PU. These characteristics can endow PU-TBN with great potential to be used as vascular implants or coatings of other materials for rapid endothelialization under complex oxidative stress environment.


Asunto(s)
Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Estrés Oxidativo , Poliuretanos/química , Pirazinas/química , Ingeniería de Tejidos/métodos , Animales , Antioxidantes/farmacología , Apoptosis , Materiales Biocompatibles , Prótesis Vascular , Adhesión Celular , Proliferación Celular , Depuradores de Radicales Libres , Radicales Libres , Humanos , Ratones , Células 3T3 NIH , Fármacos Neuroprotectores , Oxígeno/metabolismo , Adhesividad Plaquetaria , Polímeros/química , Conejos , Resistencia a la Tracción , Trombosis/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...